A large-scale, multi-center international study published in the European Heart Journal has shown that EchoGo® Amyloidosis, an AI-powered tool developed by Ultromics, significantly improves the ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

Explore how AI transforms cardiac amyloidosis detection with remarkable accuracy—keep reading to see its clinical potential.

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

AL amyloidosis can be found in newly diagnosed 2 patients with MM or can develop later in their disease course, 16 which bodes poorly for these patients. 17 Historically, the converse—that is, ...

Amyloidosis may be secondary to a different health condition or can develop as a primary condition, according to Johns Hopkins Medicine. Sometimes it is due to a mutation in a gene, ...

AA amyloidosis is an extremely rare disease, and doctors have yet to understand exactly why it shows up in some individuals and not others. The condition is, however, known to be linked to other ...

Amyloidosis is a disorder characterized by extracellular deposition of proteins in an abnormal fibrillar configuration. Amyloidosis can be localized or systemic and may affect any organ. Breast ...